Creating new drugs to help eliminate HIV-1 infection
Official title: Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication
Funded at Florida State University · NIH-11263829 · Data updated 2026-11-12
This study is looking at new ways to create medicines that target a specific part of the HIV virus to help your immune system find and fight the virus better, with the hope of finding a potential cure for HIV instead of just managing it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida State University NIH-funded |
| Lab location | 1 site (Tallahassee, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $655,537 |
| NIH project number | 7R01AI172547-03 |
| Project ID | NIH-11263829 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV-1 who are currently on antiretroviral therapy but are seeking options for a potential cure.
✕Less likely to help
Patients who are not infected with HIV-1 or those who have already developed resistance to multiple antiretroviral therapies may not benefit from this research.
What this research studies
This research focuses on developing innovative antiretroviral drugs that target the HIV-1 Nef protein, which plays a crucial role in helping infected cells evade the immune system. By inhibiting Nef, the goal is to reverse the latency of HIV-1 and enable the immune system to recognize and eliminate infected cells. The approach involves understanding the structural biology of Nef and how it interacts with immune receptors, which could lead to more effective treatments for HIV-1. Patients may benefit from these new therapies that aim for a potential cure rather than just controlling the infection.
Why it matters
Potential benefit: If successful, this research could lead to a breakthrough in HIV-1 treatment, potentially allowing for the eradication of the virus from the body.
How similar studies have gone: While the approach of targeting the Nef protein is promising, it is relatively novel and has not yet been extensively tested in clinical settings.
Where this research is happening
-
Florida State University
Tallahassee, United States Active
Researchers
- Principal investigator: Jia, Xiaofei — Florida State University
- Study coordinator: Jia, Xiaofei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.